TALLITON (Carvedilol) is a long-term cardiovascular support medication used in adult patients across several chronic clinical domains. The medication is generally used to provide supportive relief and maintain stability in conditions involving systemic imbalance. The primary therapeutic domains of use involve chronic circulatory management.

It is commonly applied in the long-term management of Chronic Heart Failure (CHF), the control of essential hypertension (high blood pressure), and for long-term stabilization following a myocardial infarction when subsequent left ventricular dysfunction is present. This application is relevant when supportive symptom management is appropriate and contributes to easing the overall symptom load.

“The use of this supportive therapy assists with maintaining functional stability during phases when symptoms become more noticeable.”

The medication supports the patient by addressing symptom clusters that may interfere with daily functioning, such as fatigue and shortness of breath upon ordinary activity. By providing sustained assistance, TALLITON helps maintain a sense of stability, particularly for patients managing conditions marked by increased physiological stress.

---

Quick Fact: Relief for Circulatory Strain TALLITON is relevant in clinical settings where the goal is to manage symptoms linked to organ-specific functional stress, providing long-term support for conditions characterized by periods of heightened symptoms and noticeable physiological strain.

---

Regulatory References

1. DailyMed official Carvedilol label

Official Population Eligibility Rules

Таллитон (Carvedilol) is officially approved for use in adult patients for the long-term management of chronic cardiovascular conditions. Eligibility is defined by a strict set of contraindications and population-specific restrictions documented in regulatory labeling.

Category	Eligibility Status (As Defined in Official Labels)
Populations for Whom Use is Contraindicated	Patients with severe hepatic impairment or bronchial asthma/related bronchospastic conditions. Also prohibited in specific severe cardiac states, including second- or third-degree AV block, sick sinus syndrome, severe bradycardia (unless a permanent pacemaker is in place), and cardiogenic shock or decompensated heart failure requiring intravenous support.
Age-Related Eligibility	Use in children and adolescents under 18 years of age is not recommended because efficacy and safety data have not been established in the pediatric population. Elderly patients may require closer monitoring.
Conditional Use/Restrictions	Caution is mandatory for patients with diabetes mellitus or non-allergic bronchospasm. Patients with chronic heart failure and a low systolic blood pressure (<100 mmHg) are at risk of reversible renal function deterioration and require monitoring.
Pregnancy and Lactation Status	Not recommended during pregnancy unless the potential benefit justifies the risk. Breastfeeding is also not recommended, as it is not known whether the medicine is excreted into human milk.

Connection to the Overall Eligibility Profile: The regulatory profile establishes absolute prohibitions based on severe pulmonary, hepatic, and cardiac dysfunction. Use is constrained by unestablished safety data in children and requires special caution and monitoring in adults with specific comorbidities, such as diabetes or renal insufficiency risk factors.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Carvedilol (TALLITON), based strictly on regulatory prescribing information.

Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with other medicines can alter the plasma concentration of Carvedilol or create additive physiological effects.

• Exposure Modification: Carvedilol concentrations may be significantly increased by co-administered CYP2D6 or CYP2C9 inhibitors (e.g., Amiodarone, Fluoxetine). Conversely, enzyme inducers such as Rifampin officially cause a reduction in Carvedilol levels.
• Transporter Effects: Carvedilol is documented to increase the blood levels of P-glycoprotein substrates, including Digoxin and Cyclosporine, requiring concentration monitoring for these agents.
• Additive Cardiovascular Effects: Combining Carvedilol with other agents that slow heart rate or lower blood pressure, such as Calcium Channel Blockers (Verapamil or Diltiazem type) or other hypotensive agents, carries an enhanced, officially recognized risk of severe bradycardia or hypotension.

Timing and Substance Constraints

• Food: Taking Carvedilol with food officially slows the rate of absorption without significantly changing the overall extent of drug availability.
• Clonidine Termination: If ending co-therapy with Clonidine, the Carvedilol must be discontinued first, followed by Clonidine gradual withdrawal several days later, as specified in the labeling.
• Population Note: Patients with severe hepatic impairment are formally contraindicated due to the high risk of drug accumulation.

The mechanism of action of Таллитон (Carvedilol) is defined by its ability to engage multiple molecular targets within the sympathetic nervous system, thereby modulating systemic functions through multiple targets.

This involves non-selective beta-adrenergic receptor antagonism (beta1 and beta2) and selective alpha1-adrenergic receptor antagonism. The blockade prevents the excitatory signals of catecholamines from stimulating the heart and constricting blood vessels. The alpha1 blockade induces vasodilation, which attenuates the increase in peripheral resistance potentially associated with the beta-blockade, influencing pathway equilibrium.

The antagonism of beta1-receptors on cardiac myocytes suppresses sympathetic drive at the tissue level. This molecular interaction interrupts the signaling sequence, resulting in a negative chronotropic effect (slowing the intrinsic rate) and a negative inotropic effect (reducing the force of contraction). The mechanism consequently reduces the metabolic requirements of the myocardium.

Furthermore, alpha1-receptor blockade in peripheral arteries promotes vascular relaxation. The resulting decrease in Systemic Vascular Resistance (Afterload) facilitates stroke volume ejection. The drug also exhibits molecular activity, including antioxidant properties, which helps modulate cellular processes involved in oxidative stress.

TALLITON (Carvedilol) is administered exclusively through the oral route as immediate-release tablets. The usage protocol involves a requirement for gradual dose titration and specific conditions for administration.

---

Administration and Dosing Schedule

The medication must be taken with food to slow absorption and minimize orthostatic effects. Dosage is individualized and follows established starting points and maximum limits.

Condition	Starting Dose (Immediate-Release)	Dosing Frequency
Chronic Heart Failure (CHF)	3.125 mg	Twice Daily (BID)
Essential Hypertension	6.25 mg	Twice Daily (BID)

---

Procedural Use and Special Conditions

Treatment requires a commitment to a long-term continuous course. The initial low dose is maintained for a specific period (e.g., at least two weeks for CHF) before attempting an incremental increase. This process of up-titration continues until the maximum tolerated or target dose is reached.

Before initiating the first dose, any signs of fluid retention must be minimized and stabilized. While immediate-release tablets may be divided, extended-release capsule forms (if applicable) must be swallowed whole and should not be crushed or chewed. Crucially, the medication must not be stopped suddenly; any cessation of use requires a gradual reduction (tapering) over time to prevent acute physical changes. No dose adjustment is generally required for moderate renal impairment, though use is not permitted in severe hepatic impairment.

Research Evidence / Overview of Studies for Таллитон

Evidence for Use in Chronic Heart Failure

Research exploring the use of TALLITON for Chronic Heart Failure (CHF) primarily includes large-scale, multicenter Randomized Controlled Trials (RCTs). These studies were designed to examine the medication's role when administered alongside other standard therapies. The main study populations included adults diagnosed with heart failure, ranging from those with mild to more severe symptoms. Researchers monitored several critical, long-term outcomes monitoring physiological strain or stress, including overall survival rates, the frequency of patient hospitalization for cardiac reasons, and changes to the heart's functional status.

Major trials and subsequent meta-analyses reported measurements of survival and hospitalization rates over the study period. Studies monitored and described group patterns in symptom patterns and functional status of the observed populations. It is important to note that the key registration studies typically followed patients for an intermediate-term duration, often averaging around six months to one year. Therefore, long-term outcomes are not fully established beyond the observation periods of these specific trials.

Evidence for Post-Myocardial Infarction Stabilization

TALLITON was studied for use in adults who were clinically stable following a recent myocardial infarction (heart attack) and who were found to have reduced heart pumping function (Left Ventricular Dysfunction, or LVD). The trials examined endpoints related to long-term mortality and serious cardiovascular events and the subsequent occurrence of another heart attack or the development of symptomatic heart failure. Studies monitored changes in the heart's structure and documented measurements of myocardial remodeling.

Evidence is primarily focused on patients who experienced reduced LVEF (LVD), and less information is available for patients whose heart function was preserved after the heart attack. While the research provides insight into short-term changes in cardiac structure, continuous monitoring over multiple years for all patients who survive a heart attack is not consistently detailed across the core regulatory summaries.

What is Still Uncertain About the Research Base for Таллитон

While the research provides context, certain limitations apply to the existing evidence base for TALLITON. One aspect where certainty remains low is the limited information available for long-term outcomes, especially beyond the follow-up durations of the key registration trials for heart failure. Studies show patterns where data for certain groups are less available, particularly for those specific comorbidities that were often excluded from the large RCTs. Comparative evidence against some newer agents within the same therapeutic class is less available. The existing research primarily describes patterns observed against placebo and older comparators.

Key Studies & References

1. Label: CARVEDILOL tablet, film coated - DailyMed (United States Regulatory/Product Monograph)

Common questions about Таллитон (FAQ)

Q: How is Tallyton different from other similar medicines?

Official product information describes Tallyton as a third-generation beta-blocker with a unique dual mechanism of action. It works on both beta-receptors to slow the heart rate and alpha-1 receptors to promote the relaxation of blood vessels. This integrated action is intended to reduce the overall workload on the heart.

Q: Can Tallyton affect the ability to drive?

Regulatory documents advise caution when initiating treatment or increasing the dose, as this may cause dizziness or lightheadedness. Because of this potential effect, official labeling suggests avoidance of driving or operating hazardous machinery until an individual is aware of how the medication affects them.

Q: How long does it take for Tallyton to achieve its full effect?

According to official clinical information, the immediate-release form of the medication may start acting within a couple of hours after ingestion. However, the full therapeutic effect that contributes to the long-term management of chronic conditions typically requires continuous use for one to two weeks before being fully observed.

Q: What does 'gradual withdrawal' of Tallyton mean?

Gradual withdrawal refers to the process where the dosage is slowly reduced over a period of time, often one to two weeks, before the medication is fully stopped. This tapering process is officially recommended to minimize the risk of a severe acute exacerbation of coronary artery disease.

Q: Does taking Tallyton affect blood test results?

Official safety information notes that this medication may cause an increase in blood glucose levels, a condition known as hyperglycemia. It may also alter the results of serum lipid profiles, such as those measuring cholesterol and triglycerides. Monitoring of renal function is also advised for certain patients who are at risk.

Q: What should be done if Tallyton causes severe drowsiness?

Dizziness and fatigue are listed as common effects in official safety documents. If these symptoms are experienced, caution is recommended, particularly when changing posture, to avoid falls. If drowsiness or dizziness is severe or persistent, reporting them to a healthcare provider is generally recommended.

Q: What is Tallyton's role in combination therapy?

The role of Tallyton is foundational in the long-term management of chronic circulatory issues. Research evidence shows it is often administered as a component of a regimen, used in combination alongside other standard therapies, such as diuretics or ACE inhibitors, particularly for the treatment of heart failure.

Q: What is 'Tallyton withdrawal syndrome'?

Regulatory warnings refer to a risk of acute exacerbation of coronary artery disease if the drug is suddenly stopped. This may manifest as worsening angina or, in rare cases, a myocardial infarction. This risk is why gradual reduction (tapering) is officially recommended prior to cessation.

Q: How long can Tallyton be taken safely?

Tallyton is officially indicated for the long-term, continuous management of chronic cardiovascular conditions. While treatment is expected to be ongoing, major registration studies typically followed patients for an intermediate duration, ranging from approximately six months to one year.

Q: What are the long-term risks associated with Tallyton?

Official research overviews indicate that the full extent of long-term outcomes beyond the typical follow-up periods of key registration trials is not entirely established. Known long-term considerations mentioned in official documents include the potential to alter serum lipid profiles and the need to monitor diabetic patients for worsening hyperglycemia.

Q: Is a special diet required while taking Tallyton?

The only official requirement regarding food is that the medication is recommended to be taken with food. This measure is included in the administration protocol to help slow the rate of absorption and minimize the potential for dizziness or lightheadedness.

Q: What should be done if an allergy to Tallyton appears?

Official safety documents list rare, serious hypersensitivity reactions, such as Angioedema. If a severe adverse reaction suspected of being an allergy is experienced, the official guidance is that the medication be permanently discontinued, and emergency medical attention is necessary.

Q: How does Tallyton 'work' in simple language?

Tallyton is a dual-action medicine that helps the heart work more efficiently. It accomplishes this by slowing the heart rate (beta-blocking effect) while simultaneously easing tension in the arterial walls (alpha-blocking effect). This action reduces the overall demand placed upon the circulatory system.

Q: What should be done if a dose of Tallyton is missed?

According to official dosing protocol, a patient may take a missed dose as soon as they remember. If, however, it is almost time for the next scheduled dose, the missed dose is typically skipped, and the regular schedule is resumed. Taking a double dose is officially advised against to make up for a missed one.

Q: What popular over-the-counter medicines is Tallyton incompatible with?

Official interaction information cautions against combining Tallyton with other drugs that slow the heart rate or lower blood pressure. Caution is also advised regarding products that affect the liver's CYP2D6 or CYP2C9 enzymes, which can include some non-prescription products.

Q: Is it necessary to change lifestyle when taking Tallyton?

Official product information advises caution regarding certain habits, specifically due to potential interactions or side effects. This includes exercising caution with alcohol consumption and avoiding driving if dizziness is experienced. Regulatory warnings also note that smoking cessation may require a dose adjustment.

Q: What should be done if side effects from Tallyton do not go away?

Regulatory guidelines suggest that if side effects are unusually troublesome, persistent after a few days, or if they become severe (such as sudden trouble breathing or rapid weight gain), contacting a healthcare professional is recommended immediately. This ensures that any change in condition is quickly assessed.

Q: Can Tallyton cause problems with memory or concentration?

The official regulatory safety profile lists adverse reactions under the classification of Nervous System Disorders. Although memory or concentration issues are not listed as common side effects, any unusual or persistent difficulties in these areas reporting them to a healthcare professional is generally suggested for proper evaluation.

Q: What should be done if an accidental double dose of Tallyton is taken?

The official product monograph describes the potential symptoms of an overdose, which include severe hypotension (very low blood pressure), bradycardia (an excessively slow heart rate), and bronchospasm. Immediate contact with emergency medical services is necessary if an excessive dose is taken, as supportive treatment may be required.

Q: Why can't Tallyton be taken with alcohol?

According to official interaction documents, alcohol may have an additive effect in lowering blood pressure when taken with Tallyton. This combination can increase the risk of side effects such as dizziness, lightheadedness, or fainting.

Q: Does Tallyton interact with herbal supplements?

Official regulatory information does not specifically list or exclude all herbal supplements from potential interactions. However, official guidance suggests informing a healthcare provider about all medicines, herbs, and supplements currently being used, as they may interact with the medication.

Q: Can coffee and energy drinks be consumed while taking Tallyton?

Official warnings advise that caffeine may have counteractive effects on this medication. Since Tallyton works to decrease blood pressure and heart rate, using products containing caffeine, such as coffee or energy drinks, may interfere with the intended therapeutic effect.

Q: Is there a risk of developing depression when taking Tallyton?

Official safety information classifies potential adverse reactions by organ systems, including Nervous System Disorders. While not listed as a common effect, any unusual or persistent changes in mood, including symptoms related to depression, reporting them to a healthcare professional is generally suggested for assessment.

Q: Can Tallyton interact with contraceptives?

Official drug interaction summaries suggest that this medication is not typically expected to reduce the effectiveness of hormonal birth control pills. It is recommended that a patient ensures their prescribing physician is aware of all forms of contraception being used.

Q: Is there a difference in Tallyton's effect when taken morning and evening?

The immediate-release tablet is typically prescribed to be taken twice a day, or BID, to ensure a continuous therapeutic effect over a 24-hour period. To maintain consistent blood levels, doses are often recommended to be taken as close to 12 hours apart as is practical.

Q: Does Tallyton affect the ability to exercise?

Due to its beta-blocking effects, the medication may reduce or attenuate the body's natural cardiovascular response during exercise or strenuous physical activity. This means the normal increase in heart rate or blood pressure during exercise may be less pronounced than usual.

Q: Can Tallyton be taken with vitamins?

Official interaction information indicates that taking the medication together with multivitamins that contain minerals may potentially decrease the effect of Tallyton. It is recommended that the administration times be separated by at least two hours to prevent this.

Q: Can Tallyton cause mood changes other than those related to the treatment?

As with other potential adverse reactions, any unusual or persistent changes in mood or disposition are classified under the system of Nervous System Disorders in official safety documents. Discussion with a healthcare professional is suggested if these symptoms occur.

Q: Are there known genetic factors that influence the reaction to Tallyton?

Official product information details that the medication is metabolized by liver enzymes, specifically CYP2D6 and CYP2C9. Since these enzyme systems can be affected by genetic variations among patients, the drug's concentration in the body may differ depending on an individual's genetic profile.

How to Store and Dispose of Tallyton (Carvedilol)

The storage and disposal of Tallyton must strictly adhere to instructions provided in official regulatory labeling.

Official Storage Requirements

Tallyton tablets must be stored at a temperature not exceeding 30^circC (86°F). The product must be protected from moisture and must not be refrigerated or frozen. For safety, the medication must be stored out of the reach and sight of children. To maintain product stability and the official 3-year shelf-life, the tablets must remain in the original container and be kept tightly closed.

Disposal Instructions

Expired or unused Tallyton must be handled as pharmaceutical waste. Do not dispose of the medication in household trash or pour it down the sink or toilet (wastewater). Disposal must occur through an authorized drug take-back program or a designated local collection point.